Home >  News >  Industry >  Pharma News >  COVID vaccine: Moderna...

COVID vaccine: Moderna wins patent case in Europe against Pfizer, BioNTech

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-05-19 07:30 GMT   |   Update On 2024-05-19 07:31 GMT
Advertisement

London: Moderna announced on Friday that it has emerged victorious in a case at the European Patent Office against Pfizer and BioNTech concerning its COVID-19 vaccine. The company has been engaged in a protracted legal dispute with its competitors over Pfizer-BioNTech's COVID shot Comirnaty since initiating legal action in 2022, alleging copying its mRNA technology.

Pfizer and BioNTech have also countersued, alleging that Moderna's patent is invalid.
Advertisement
The vaccine makers were the first to develop their COVID shots, which led to a revenue windfall during the pandemic.
Moderna said it expects its opponents to appeal the European Patent Office's decision.
Pfizer said it was disappointed and would consider all legal options and may appeal the decision. BioNTech did not immediately respond to Reuters request for comment.
"Irrespective of the outcome of this legal matter, we will continue to manufacture and supply the Pfizer-BioNTech COVID-19 vaccine," Pfizer said in a statement to Reuters.
The oral decision by the European Patent Office was handed down on Thursday, the Financial Times said, which was the first to report on the matter. The report added that a written decision is expected to be published in the coming months.
Pfizer, BioNTech and Moderna are also involved in parallel proceedings related to their patents in Germany, the Netherlands, Belgium, England and the United States.
Last month, a Massachusetts federal court put a patent lawsuit on hold, while the U.S. Patent Office determines whether two of the three Moderna patents at issue are valid.
Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

42 dead, 8 still missing in Sigachi pharma plant explosion

Akums Drugs and Pharma: Jitendra Mishra steps down as Senior Vice President - IT

Biocon Biologics gets marketing nods in UK for Vevzuo, Evfraxy

Indian pharma exports strong at USD 4.9 billion in April-May: Pharmexcil

Expert Panel Approves Post-Marketing Surveillance Study of Eculizumab (Soliris) by AstraZeneca in India

Emcure Pharma incorporates new wholly-owned subsidiary Emcure Wellness

JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterations

Govt Panel Proposes Braille Cards, Voice-Enabled QR Codes on Medicine Packs to Aid Visually Impaired